Bevacizumab: the phoenix of breast oncology?
نویسندگان
چکیده
منابع مشابه
Monitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab
Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy or side effects associated with this type of treatment often appear to be sporadic. Bevacizumab is...
متن کاملthe study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولBevacizumab for Metastatic Breast Cancer
Breast cancer is the most common cancer among women; it also contributes to a substantial proportion of the global cancer burden1. At diagnosis, metastatic breast cancer (mbca) accounts for 5%–10% of all breast cancers2. Molecular subtyping is essential when choosing a treatment for mbca. The most commonly used biomarkers of treatment response are the estrogen and progesterone hormone receptors...
متن کاملBevacizumab in the treatment of metastatic breast cancer.
Increased levels of vascular endothelial growth factor (VEGF) have been associated with a poor prognosis for patients with breast cancer. In addition to its prognostic role, VEGF is also a validated target in the treatment of this disease. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination wi...
متن کاملBevacizumab in the treatment of HER2-negative breast cancer
Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Oncology
سال: 2015
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(15)70201-9